[
  {
    "ts": null,
    "headline": "Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=5501bc169dc42d26605b8693ec61173cddcba54dbad78890e8d9016a4f2e4970",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751579404,
      "headline": "Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 135743626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=5501bc169dc42d26605b8693ec61173cddcba54dbad78890e8d9016a4f2e4970"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d61f3b443037c8f86cb26dbe4d661cf42b9fa0728edebbfa21c10984f816d609",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751560440,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "id": 135859335,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d61f3b443037c8f86cb26dbe4d661cf42b9fa0728edebbfa21c10984f816d609"
    }
  },
  {
    "ts": null,
    "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
    "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
    "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751549160,
      "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
      "id": 135735715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
      "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3"
    }
  },
  {
    "ts": null,
    "headline": "MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE",
    "summary": "Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.",
    "url": "https://finnhub.io/api/news?id=0dd18af311cd9a7e7ae84482050a885bb1913339fd6b10da65693d99733b4171",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751545800,
      "headline": "MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE",
      "id": 135735537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.",
      "url": "https://finnhub.io/api/news?id=0dd18af311cd9a7e7ae84482050a885bb1913339fd6b10da65693d99733b4171"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
    "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
    "url": "https://finnhub.io/api/news?id=360d9ba1a355d3457eb618cc67af06143082c0c6ea67ffb8c98a8ea48247c5bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751545200,
      "headline": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
      "id": 135735490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
      "url": "https://finnhub.io/api/news?id=360d9ba1a355d3457eb618cc67af06143082c0c6ea67ffb8c98a8ea48247c5bf"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review for WINREVAIR (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial",
    "summary": "RAHWAY, N.J. - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental...",
    "url": "https://finnhub.io/api/news?id=7385827f2b6b903bfa062af99f31435f0ffa88b2340e8c3b96f0f521f8104240",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751539102,
      "headline": "FDA Grants Priority Review for WINREVAIR (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial",
      "id": 135734595,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY, N.J. - Merck , known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental...",
      "url": "https://finnhub.io/api/news?id=7385827f2b6b903bfa062af99f31435f0ffa88b2340e8c3b96f0f521f8104240"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To […]",
    "url": "https://finnhub.io/api/news?id=eea4c1a749b222e0694f3812b7bad5e0f44c55afa7ab067f2ec3f4b484ae467b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751525244,
      "headline": "Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease",
      "id": 135735718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To […]",
      "url": "https://finnhub.io/api/news?id=eea4c1a749b222e0694f3812b7bad5e0f44c55afa7ab067f2ec3f4b484ae467b"
    }
  }
]